title: Why targeting? Physiological, pharmacological, and economic aspects.
authors.affiliation: SmithKline Beecham Pharmaceuticals, Harlow, Essex, United Kingdom.
authors.forename: R
authors.initials: R
authors.lastname: Fears
mesh_terms: D000818:Animals; D003328:Coronary Thrombosis / Q000188:drug therapy* / Q000517:prevention & control; D005337:Fibrin / Q000378:metabolism; D005342:Fibrinolysis; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D008954:Models, Biological; D009203:Myocardial Infarction / Q000188:drug therapy / Q000517:prevention & control; D010960:Plasminogen Activators / Q000502:physiology / Q000627:therapeutic use; D013927:Thrombosis / Q000188:drug therapy* / Q000517:prevention & control
chemical_list: D005343:Fibrinolytic Agents; D005337:Fibrin; D010960:Plasminogen Activators